miR-200b as a prognostic factor in breast cancer targets multiple members of RAB family

Table 1 Clinico-pathological variables and the expression of miR-200b in total breast cancer patients

Characteristics	Total (n = 134)	miR-200b low (n = 78)		miR-200b high (n = 56)		P value
Characteristics	Total (n = 134)	No.	%	No.	%	P value
Age (years)						0.330
<50	82	46	56.1	36	43.9
>50	52	32	61.5	20	38.5
Menopause						0.524
Yes	63	37	58.7	26	41.3
No	71	41	57.7	30	42.3
LN infiltrated						0.148
Yes	80	50	62.5	30	37.5
No	54	28	51.9	26	48.1
Tumor size (cm)						0.080
= < 2	38	18	47.3	20	52.7
>2	96	60	62.5	36	37.5
TNM stage						0.040*
I-II	78	40	51.3	38	48.7
III- IV	56	38	67.9	18	32.1
Local relapse						0.083
Yes	8	7	87.5	1	12.5
No	126	71	56.3	55	43.7
Distant metastasis						0.003*
Yes	34	27	79.4	7	20.6
No	100	51	61.0	49	49.0
ER status						0.155
Positive	51	33	64.7	18	35.3
Negative	83	45	54.2	38	45.8
PR status						0.073
Positive	54	36	66.7	18	33.3
Negative	80	42	52.5	38	47.5
HER-2 status						0.213
Positive	22	15	68.2	7	31.8
Negative	112	63	56.3	49	43.8
TNBC status						0.472
TNBC	51	29	56.9	22	43.1
Non-TNBC	83	49	59.0	34	41.0

*means statistically significant (p < 0.05).
% means percentage within the row.
TNBC, triple-negative breast cancer, means ER(-), PR(-), HER-2(-). High expression of miR-200b was seen in 41.8% of total patients and correlated with early TNM stage (p = 0.040) and fewer metastasis (p = 0.003).

ISSN: 1479-5876